Previous Article | Next Article ![]()
Journal of Virology, March 1999, p. 2376-2384, Vol. 73, No. 3
Vertebrate Biocontrol CRC, CSIRO Wildlife and
Ecology, Canberra, Australia
Received 17 September 1998/Accepted 8 December 1998
A 4.7-kb region of DNA sequence contained at the right end of the
myxoma virus EcoRI-G2 fragment located 24 kb from the right end of the 163-kb genome has been determined. This region of the myxoma
virus genome encodes homologs of the vaccinia virus genes A51R, A52R,
A55R, A56R, and B1R; the myxoma virus gene equivalents have been given
the prefix M. The MA55 gene encodes a protein belonging to the kelch
family of actin-binding proteins, while the MA56 gene encodes a member
of the immunoglobulin superfamily related to a variety of cellular
receptors and adhesion molecules. A novel myxoma virus early gene,
MST3N, is a member of the eukaryotic sialyltransferase gene family
located between genes MA51 and MA52. Detergent lysates prepared from
myxoma virus-infected cell cultures contained a virally encoded
sialyltransferase activity that catalyzed the transfer of sialic acid
(Sia) from CMP-Sia to an asialofetuin glycoprotein acceptor. Analysis
of the in vitro-sialylated glycoprotein acceptor by digestion with
N-glycosidase F and by lectin binding suggested that the
MST3N gene encodes an enzyme with Gal The South American myxoma virus
(MYXV) is the type virus of the genus Leporipoxvirus of the
family Poxviridae (18). MYXV naturally infects
the Brazilian tapeti (forest rabbit [Sylvilagus brasiliensis]), causing the development of a small localized
tumor which can persist for several months. In contrast to the trivial symptoms in its natural host, infection of the European rabbit (Oryctolagus cuniculus) causes the often fatal disease
myxomatosis. The Californian MYXV isolates which naturally infect the
brush rabbit (Sylvilagus bachmani) also cause fulminant
disease in the European rabbit (20). Other recognized
members of the genus Leporipoxvirus include Shope fibroma
virus (SFV; natural host, Eastern cottontail [Sylvilagus
floridanus]), hare fibroma virus (natural host, European brown
hare [Lepus europaeus]), and the squirrel fibroma virus
(natural host, gray squirrel [Sciurus carolinensis]).
MYXV is known to encode a variety of cell-associated and secreted
proteins which have been implicated in down-regulation of the host's
immune and inflammatory responses (37, 38) and inhibition of
apoptosis of virus-infected cells (36). These virulence
genes are encoded either within or adjacent to the 11.5-kb inverted
terminal repeats present at either end of the 163.6-kb genome. As with
other poxviruses, the central "conserved" region of the MYXV genome
(~140 kb) is presumed to encode genes primarily involved in nucleic
acid synthesis and virion morphogenesis (25-27). Here we
describe the identification of a new poxvirus gene encoded within the
central region of the MYXV genome that belongs to the eukaryotic
sialyltransferase family. The sialyltransferase family comprise more
than 15 different membrane-bound glycosyltransferases of the
trans-Golgi network (TGN) that catalyze the transfer of sialic acid (Sia) from CMP-Sia to the nonreducing terminal positions of
N- and O-glycan of glycoproteins and
oligosaccharide of glycolipids (49). Terminal Sia of
glycoconjugates are known to play important biological roles in (i)
maintenance of serum glycoproteins in circulation, (ii) receptor-ligand
interactions between cells involved in immune and inflammation
responses, (iii) enhanced metastatic capability of tumor cells, (iv)
masking of receptors and antigens on tumor cells and microorganisms,
and (v) viral attachment to target cells (for an extensive review of
the biological roles of carbohydrates, see reference
60). Sialylation of virus- or host-encoded
glycoproteins could thus have multiple influences on MYXV's attempts
to subvert the rabbit's innate and acquired responses to infection.
Cells and viruses.
SIRC (O. cuniculus cornea
[ATCC CCL-60]), RK13 (O. cuniculus kidney [ATCC CCL-37])
and CV-1 (African green monkey [Ceropithecus aethiops]
kidney [ATCC CCL-70]) were maintained in minimal essential medium
(MEM) supplemented with 5% (vol/vol) fetal bovine serum. Poxviruses
were grown on the cells described above in MEM supplemented with 0.5%
(vol/vol) fetal bovine serum.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Myxoma Virus Encodes an
2,3-Sialyltransferase
That Enhances Virulence
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
1,3(4)GlcNAc
2,3-sialyltransferase specificity for the N-linked oligosaccharide of glycoprotein. Lectin binding assays demonstrated that
2,3-sialyltransferase activity is expressed by several known
leporipoxviruses that naturally infect Sylvilagus rabbits.
The sialyltransferase is nonessential for myxoma virus replication in
cell culture; however, disruption of the MST3N gene caused attenuation
in vivo. The possible implications of the myxoma virus-expressed
sialyltransferase in terms of the host's defenses against infection
are discussed.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
DNA sequencing and plasmid constructions.
In the MYXV Ur
strain, a 7.3-kb EcoRI-G2 DNA fragment located approximately
131.9 to 139.2 kb from the left end of 163.6-kb viral genome
(27) was ligated into the vector pGem7Zf(
) (Promega Corporation, Madison, Wis.). A 4.7-kb DNA sequence, including the
4.3-kb BamHI-N fragment plus sequences to the right end of the EcoRI-G2 fragment (GenBank accession no. U46577), was
determined from both strands by using the ABI PRISM Dye Primer Cycle
Sequencing Ready Reaction kit and an ABI DNA sequencer (Applied
Biosystems, Perkin-Elmer, Foster City, Calif.).
P11. The MYXV Lu strain
ClaI-EcoRV fragment containing the Lu MST3N gene
together with its natural early promoter was isolated and ligated
between the ClaI and HincII sites of pBluescript
SK
(Stratagene), generating pBS-ST. The
EcoRI-XhoI fragment containing the Lu MST3N gene
and its promoter was excised from pBS-ST and ligated between the
EcoRI and SalI sites of pUrTK11
P11, generating
pUrTK11
P11/Lu-MST3N.
Recombinant myxoma viruses.
(i) Lu243Z (27) is a
lethal grade I virus (>99% mortality,
13-day mean survival time
[21]) which contains a synthetic late promoter and the
E. coli lacZ gene inserted in the intergenic region between
the MYXV
-subunit RNA polymerase (MA24) and the fusion protein
(MA27) genes. (ii) MST3N gene knockout virus Lu(lacZ+/MST3N
) was
constructed by the transient dominant selection procedure (19) using the plasmid pUrST1-lacZ and
Lu-infected RK13 cells. This virus contains a synthetic late promoter
and the E. coli lacZ gene interrupting the MST3N gene. (iii)
Lu(lacZ+/Lu-MST3N+) was constructed by transfection of
Lu(lacZ+/MST3N
)-infected RK13 cells with pUrTK11
P11/Lu-MST3N and
selection for gpt gene expression by using mycophenolic acid
(20 µg/ml), xanthine (250 µg/ml), hypoxanthine (15 µg/ml),
aminopterin (2 µg/ml), and thymidine (10 µg/ml), which were added
to the culture medium. Lu(lacZ+/Lu-MST3N+) contains an interrupted and
inactive copy of the natural MST3N gene and a second intact copy
inserted in the intergenic region between the thymidine kinase
(tk, MJ2) and MJ2a genes (27). Expression of the
MYXV-encoded
2,3-sialyltransferase by these recombinant viruses was
determined with the lectin binding assay described below.
Viral mRNA preparation and Northern blot analysis. RK13 cells were infected with MYXV at 10 PFU/cell and incubated in MEM for 16 h for the isolation of late viral mRNA or were incubated in MEM supplemented with 100 µg of cycloheximide per ml (Sigma Chemical Co., St. Louis, Mo.) for 10 h for early viral mRNA preparation. Poly(A)+ RNA was isolated from the infected cells by using the PolyATract System 1000 (Promega Corporation). A strand-specific 32P-labeled RNA probe complementary for the MST3N mRNA was prepared by using the Riboprobe Gemini II kit (Promega Corporation) and pUrS-R2. The Northern transfer, hybridization, and washing stringency procedures were performed as recommended by the manufacturer.
Cell lysate preparation.
Confluent monolayers of CV1 cells
were infected with poxvirus at 1 PFU/cell in 80-cm2 culture
flasks. Twenty-four hours postinfection, the cells were detached from
the culture flasks with a cell scraper and washed three times by using
phosphate-buffered saline (PBS) at 4°C. Cell lysates were prepared by
suspension in 1 ml (per flask) of a mixture of 50 mM
2-[N-morpholino]-ethanesulfonic acid (MES)-OH (pH 6.1), 0.5% (vol/vol) Triton X-100, 100 mM NaCl, 1.5 mM MgCl2,
0.1 mM phenylmethylsulfonyl fluoride, and 10 µg of aprotinin per ml
and incubated at 4°C for 45 min. The lysate was clarified by
centrifugation at 1,750 × g at 4°C for 15 min.
Cleared lysates were stored at
70°C. Total protein concentrations
were measured by using the bicinchoninic acid protein assay reagent
(Pierce, Rockford, Ill.).
Sialyltransferase reactions.
Cell lysates, at concentrations
of 30 µl (containing ~50 µg of total protein), were mixed with 5 µl of asialofetuin {type I; Sigma Chemical Co. (10 mg/ml dissolved
in MEST buffer, which was composed of 50 mM MES-OH [pH 6.1] and 0.5%
[vol/vol] Triton X-100)} and 5 µl of CMP-[3H]Sia
(DuPont NEN, Boston, Mass. [1 µCi/µl dissolved in MEST buffer]) and incubated for 90 min at 37°C. Reactions were terminated by heating at 90°C for 10 min. An assay containing a sample lysate prepared from VACV-infected cells was used as a negative control. A
positive control consisted of the VACV-infected cell lysate including 5 mU of N-acetyllactosamine
2,6-sialyltransferase ST6Gal-I [rat liver; Boehringer-Mannheim GmbH, Mannheim, Germany]).
Peptide N-glycosidase F (PNGase F) digestion.
The total proteins from the sialyltransferase reactions were
precipitated by overnight incubation with 8 volumes of acetone at
20°C and recovered by centrifugation for 30 min with a
microcentrifuge. Protein pellets were dried and resuspended in 10 µl
of H2O. The protein samples were denatured by the addition
of 25 µl of 0.1 M
-mercaptoethanol-0.5% (wt/vol) sodium dodecyl
sulfate (SDS) and heated at 100°C for 5 min. Samples were cooled to
room temperature, and the total volume was adjusted to 40 µl with
H2O. Denatured protein aliquots of 5 µl were mixed with 5 µl of 2× PNGase F buffer {40 mM sodium phosphate buffer [pH
7.2], 20 mM EDTA, 3% [wt/vol] 3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate CHAPS}. Reactions were initiated by the addition of 0.4 U of
N-glycosidase F (Boehringer Mannheim) and incubated at
30°C for 16 h. The reactions were terminated by heating at
100°C for 5 min.
Fluorography. Samples containing approximately 6 µg of the acceptor glycoprotein were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and stained with Coomassie blue to ensure equivalent loading of acceptor glycoprotein per lane. Fluorographic detection of the tritium-labeled sialoglycoproteins was achieved by impregnating the stained gels with Amplify (Amersham International Plc., Little Chalfont, United Kingdom), drying them at 80°C, and exposing them for 24 to 48 h to preflashed Hyperfilm-MP (Amersham International Plc.).
Determination of sialic acid linkage by lectin binding.
For
sialylation of acceptor glycoprotein, 30 µl of Triton lysates
prepared from poxvirus-infected cells (~50 µg of total protein) was
mixed with 5 µl of asialofetuin (10 mg/ml) and 10 µl of CMP-Sia (10 mM [CMP-NeuAc; Sigma Chemical Co.]) and incubated at 37°C for
3 h. Glycoprotein samples (~12 µg of acceptor glycoprotein) were separated by SDS-PAGE and electrophoretically transferred to
polyvinylidene difluoride Hybond membrane (Amersham International Plc.). Determination of the bound Sia linkage to glycoprotein acceptor
was accomplished with the digoxygenin (DIG) glycan differentiation kit
(Boehringer-Mannheim), by using DIG-labeled lectins, Sambucus nigra agglutinin (SNA [for
2,6-linked Sia]), and
Maackia amurensis agglutinin (MAA [for
2,3-linked Sia])
as recommended by the manufacturer.
Virulence assays.
Animal studies were conducted in
accordance with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes. Outbred domestic rabbits raised in the
CSIRO Wildlife and Ecology animal facility were housed in individual
cages at a controlled ambient temperature of 22°C with a 12-h light
cycle. Water and food were available at all times, and green feed was provided weekly. Virulence assays followed the format of Fenner and
Marshall (21). For each virus [Lu243Z, Lu(lacZ+/MST3N
) or
Lu(lacZ+/Lu-MST3N+)], six domestic male rabbits greater than 5 months
old were inoculated by intradermal injection into the right flank with
100 PFU of virus in 100 µl of PBS. Animals were observed twice daily,
and clinical signs were recorded. Times of death were determined to the
nearest half day. Moribund animals were killed by an overdose of
barbiturate intravenously, and the time of death increased by half a
day. Once clinical signs of myxomatosis were present, all rabbits were
injected twice daily subcutaneously with 0.75 to 0.9 mg of the
analgesic buprenorphine as advised by the Institute Animal Ethics
Committee. This has previously been demonstrated not to alter the
survival time of rabbits infected with virulent myxoma virus. Results
were determined as average survival times of rabbits infected with each
virus, and statistical significance was examined by pairwise Student's t tests.
Nucleotide sequence accession number. The nucleotide sequence data reported in this article have been deposited with the GenBank database and have been assigned accession no. U46577, U46578, and AF030894.
| |
RESULTS |
|---|
|
|
|---|
DNA sequence and protein similarities.
The deduced 4.7-kb DNA
sequence (Fig. 1) contains six major
ORFs. The MYXV ORFs have been termed MA51 (partial sequence), MA52,
MA55, MA56, and MB1 (partial sequence), to correspond to the gene
homologs encoded by the Copenhagen strain of VACV (23); and
MST3N, designating the
2,3-sialyltransferase gene. Homologs of the
VACV A53R (tumor necrosis factor receptor related), A54R, and A57R
(guanylate kinase related) genes are not encoded in this region of the
MYXV genome. The inferred amino acid sequences of the MYXV ORFs were
compared to sequences in the nonredundant protein databases by using
the gapped-BLASTp (V2.0.2) program (2).
|
ORFs MA51, MA52, and MB1. The MA51- and MA52-encoded proteins only share significant similarity to the corresponding Orthopoxvirus homologs. The VACV A51R and A52R genes are nonessential for VACV replication (23), and in VARV, the A52 gene homolog is fragmented into multiple short ORFs (35). The MB1 gene encodes the MYXV homolog of the VACV serine/threonine protein kinase (23).
ORF MA55.
The MA55-encoded protein shares amino acid
similarity with the actin-associated proteins kelch (66),
MIPP (9), scruin (64, 65), and calicin
(62); multiple poxvirus-encoded proteins, including VACV
A55R, C2L, F3L (23), and MYXV T8, and T9
(57); and many Drosophila and mammalian zinc
finger proteins. The MA55 protein contains an amino-terminal poxvirus
zinc finger (POZ) domain, which is thought to be involved in the
formation of hetero- and homoprotein dimers and which is usually found
in the first 120 amino acids of actin-associated or zinc finger DNA
binding proteins (1). The shared amino acid similarity
between MA55 and the zinc finger proteins is restricted to the POZ
domain. The MA55 protein does not contain consensus zinc finger motifs and is therefore unlikely to be directly involved in transcription regulation. The amino acid similarity between the MA55 protein and the
actin-associated proteins extends beyond the POZ domain and includes
six imperfect repeats (kelch repeats) of approximately 50 amino acids
each (R1, amino acids 252 to 300; R2, 301 to 347; R3, 348 to 394; R4,
395-445; R5, 446-498; and R6, 499-545) found in the COOH-terminal
region. Kelch repeats are predicted to form antiparallel
-strand
"superbarrel" folds which have been implicated in actin binding
(4, 52). This suggests that the MA55 early protein (see
below) could be involved in altering the actin cytoskeleton during the
early stages of the viral replication. Like the Drosophila kelch protein (47), the MA55 protein could bind actin
through the kelch repeats and then cross-link the actin filaments via MA55 dimerization mediated through the POZ domain.
ORF MA56. The results of a BLASTp similarity search indicated that the MA56 protein shares similarity to the Xenopus laevis neural cell adhesion molecule (N-CAM) isoforms (55) and the raccoonpox virus hemagglutinin (HA) (8); however, it is only distantly related to the VACV A56R HA protein. A similarity search conducted by using a BLITZ analysis identified significant amino acid similarity to additional cellular receptors and adhesion proteins, including yeast A-agglutinin attachment subunit (48), mouse type II interleukin 1 receptor (39), Orthopoxvirus HAs encoded by VACV (23) and VARV (35), and numerous other members of the immunoglobulin superfamily.
The MA56 protein contains an N-terminal type I signal sequence (amino acid residues 1 to 18), transmembrane domain (amino acids 197 to 213) predicted by using PSORT analysis (42), and an immunoglobulin domain (amino acid residues 33 to 105) predicted by using the Pfam-A HMM search (release 2.0) (54). Potential N glycosylation sites (NX[ST], residues 23, 32, 38, 56, 84, 92, 121, and 148) and phosphorylation sites (PKC [ST]X[RK]; residues 18, 51, 69, 117, 141, 147, 151; CK-2 [ST]-XX-[DE]; residues 26, 69, 74, and 94) are contained in the MA56 protein. The protein is rich in serine (18%) and threonine (14%) residues with multiple potential O glycosylation sites (Thr residues 110, 123, 124, 128, 129, 147, 151, and 189; Ser residues 113, 126, 150, 180, 181, 182, 185, 186, 187, 190, and 191), predicted by using NetOGlyc (V2.0) analysis (24). Like the Orthopoxvirus HA protein (46), the mature MA56 protein is likely to be expressed as a type I integral plasma membrane phosphoglycoprotein and is potentially a "viroreceptor," with the oligosaccharide moiety involved in the binding to an uncharacterized ligand.The MST3N gene.
The MST3N gene encodes a protein with
significant amino acid similarity to a range of eukaryotic
sialyltransferases with different enzymatic activity toward the
N- and O-glycans of glycoproteins and
oligosaccharide of glycolipids (49). The MST3N product
contains a noncleavable signal-transmembrane sequence between amino
acid residues 7 and 28. Like all known glycosyltansferases, the MST3N protein is predicted to be a type II integral membrane protein with the
NH2-terminal region (residues 1 to 6) on the cytoplasmic side of the membrane with the catalytic domain of the protein in the
TGN lumen. The MYXV MST3N protein lacks a large proteolytically sensitive stem region, which is commonly found between the type II
signal and the catalytic domain of other sialyltransferases (49). Recognizable motifs in the MST3N protein include an
L-sialyl motif (amino acids 83 to 127;
C-I-V-V-G-N-S-Y-N-L-H-N-R-S-L-G-R-I-I-D-S-Y-N-V-V-F-R-L-N-D-A-P-V-R-A-F-E-R-D-V-G-T-K-T) involved in binding the CMP-Sia nucleotide donor (12) and an S-sialyl motif (amino acids 219 to 242;
P-T-M-G-M-V-A-L-V-T-A-L-H-V-C-Q-G-V-T-I-T-G-F-G). The conserved
cysteines of the two sialyl motifs are proposed to form a disulfide
linkage that is required for correct folding and enzyme activity
(13). The MST3N protein S-sialyl motif region is predicted
to form an
-helical hydrophobic domain. The MYXV S-sialyl motif
region is unlikely to be a second transmembrane domain, since the
S-sialyl motif has been implicated in binding both donor and acceptor
substrates (13) and would be unavailable if embedded in the
TGN membrane. The MST3N protein contains several potential N-linked
glycosylation sites (residues 34, 45, 95, 147, and 283); however, it is
not predicted to contain O-linked oligosaccharide, as determined by
using NetOGlyc analysis.
MYXV gene transcription. All of the ORFs contained on the MYXV BamHI-N fragment (nucleotides 1 to 4278 [Fig. 1]) are likely to be transcribed early in infection. Upstream of the MST3N, MA52, MA55, and MA56 ORFs are found A-rich sequences that are similar to those of the poxvirus early promoter consensus motif [AAAAAATGAAAAAA(C/T)A] (14). The ORFs MA51 (partial sequence), MST3N, MA52, and MA55 do not contain early transcription termination motifs [TTTTTNT] (67); however, such motifs are found downstream of both the MA51 and MST3N ORFs, again suggesting these genes are transcribed early in infection. ORF MA56 has a TTTTTNT sequence located within the 3'-end region of the gene, suggesting the putative MA52, MA55, and MA56 early mRNAs have coterminal 3' ends with transcriptional termination occurring downstream of the MA56 stop codon. The MA56 ORF does not contain an upstream late promoter transcription initiation motif [TAAAT(G/A)] (15); therefore, temporal expression of MA56 will differ from that of the early and late expressed VACV HA genes (6). Immediately upstream of the MB1 protein kinase gene is a late promoter initiation motif preceded by a potential early promoter, suggesting that the expression of MYXV protein kinase gene could be constitutive.
Direct evidence that the MST3N gene is transcribed during the early phase of infection was determined by Northern blot hybridization (Fig. 2). A strand-specific MST3N gene probe hybridized to a major early mRNA of approximately 1.3 kb, which is in agreement with the predicted positions of the proposed early promoter and transcription termination signal. The smaller early RNA species may have resulted from transcriptional interference from MA51 transcripts due to the artificial early RNA amplification in the presence of cycloheximide. Southern blot hybridization with the MST3N gene probe indicated there are no additional related sequences in the MYXV genome (data not shown).
|
Myxoma virus-encoded sialyltransferase activity.
Triton X-100
extracts prepared from CV1 cells infected with either VACV, Lu, or
Lu(lacZ+/MST3N
) were used for in vitro sialyltransferase reactions
(Fig. 3). Lysates prepared from
Lu-infected cells contained significant levels of sialyltransferase
activity that transferred [3H]Sia to the asialofetuin
acceptor, whereas, the VACV-infected cell lysates did not contain
detectable levels of sialyltransferase activity. The addition of the
N-glycan ST6Gal-I to the VACV-infected cell lysates
indicated they contained no general inhibitors of sialyltransferase
activity. Insertional inactivation of the MST3N gene in the recombinant
virus Lu(lacZ+/MST3N
) abolished the observed sialyltransferase
activity in MYXV-infected cells. This strongly suggests that the
observed sialyltransferase activity was encoded by the MST3N gene and
is unlikely to result from induction of a cellular activity resulting
from MYXV infection.
|
2,3 linkage to N-glycan of the asialofetuin glycoprotein acceptor.
|
2,3-Sialyltransferase encoded by other leporipoxviruses.
RK13 cells were separately infected with different leporipoxviruses
available in Australia; Brazilian MYXV Lu, two strains of Californian
MYXV (MSD and MSW), and the SFV. Lectin MAA binding assays demonstrated
that expression of
2,3-sialyltransferase activity is common to all
of the leporipoxviruses tested (data not shown). Unfortunately viable
samples of both hare and squirrel fibroma viruses were not available to
determine if expression of
2,3-sialyltransferase is also a feature
of leporipoxviruses which infect other lagomorphs and rodents.
Isolation of the
2,3-sialyltransferase genes carried by these
viruses was attempted by PCR. The Brazilian and Californian MYXV
templates produced 1.8-kb PCR products of the expected size. The PCR
products generated from the Lu and MSD virus templates were cloned, and
the DNA sequences of the Lu-MST3N (GenBank accession no. U46578) and
MSD-MST3N (GenBank accession no. AF030894) genes were determined.
6)
(34). It is possible that the minor nucleotide differences between the Lu and Ur sequences could be due to errors resulting from
the PCR DNA amplification. The Lu and Moses strains of MYXV were both
originally isolated approximately 40 years apart from the regions
surrounding Rio de Janeiro and Sãn Paulo, Brazil. The Moses
strain was propagated in laboratory rabbits for many years before being
released in Australia in 1950 followed by isolation of the attenuated
Ur strain in 1953. The DNA sequencing results indicate that the Lu and
Ur strains of MYXV have highly conserved DNA sequences despite the
years between the original isolation and the subsequent adaptation of
the viruses to a new host in Australia. In contrast, with the
Californian MSD strain, which evolved separately in its host, S. bachmani, the MSD-MST3N gene PCR product has only 84% nucleotide
identity, 84% amino acid identity, and 92% similarity relative to the
Ur-MST3N gene. A PCR product cold not be generated by using the SFV DNA
template and degenerate primers described here. Southern blot
hybridization of SFV DNA by using the Ur-MST3N gene-specific probe and
low-stringency washing localized the SFV
2,3-sialyltransferase gene
to the BamHI-F2 fragment (data not shown). This suggests
that the SFV-ST3N gene is encoded in the equivalent location to MYXV,
in the region between the genes encoding the SFV homologs of the A50R
DNA ligase (45) and the B1R protein kinase (58).
Virulence assays.
The results for rabbits infected with each
virus are shown in Fig. 5 as stepwise
survival graphs. Clinically, all three viruses induced classic
myxomatosis in the inoculated rabbits. The clinical signs developed
more rapidly in the Lu243Z control, which was clearly more virulent
than the sialyltransferase knockout Lu(lacZ+/MST3N
) virus. Survival
times were prolonged for rabbits infected with the sialyltransferase
knockout, although all but one rabbit died. For humane reasons, this
rabbit was euthanized 21 days postinfection. The sialyltransferase
revertant virus Lu(lacZ+/Lu-MST3N+) was highly virulent and was
difficult to distinguish from the Lu243Z virus clinically, although
lesions at the primary inoculation site were recorded as black in the
center a day later for the Lu(lacZ+/Lu-MST3N+) virus. In addition,
deaths of the infected rabbits commenced later, suggesting the virus
was slightly attenuated, possibly due to the extra genetic load
resulting from the DNA insertions or additional uncharacterized
mutations generated during cell culture passage.
|
), 15.7 ± 3 days; and
Lu(lacZ+/Lu-MST3N+), 12.3 ± 0.6 days. Based on the classification
of Fenner and Marshall (21), viruses Lu243Z and
Lu(lacZ+/Lu-MST3N+) are both of grade I virulence (>99% mortality,
13-days mean survival time). The virus Lu(lacZ+/MST3N
), while still
virulent, would be classed as showing grade II virulence (95 to 99%
mortality, 13- to 16-day mean survival time). The average survival time
of each virus was significantly different from that of the others as
follows: Lu243Z versus Lu(lacZ+/MST3N
), P < 0.001;
Lu(lacZ+/Lu-MST3N+) versus Lu(lacZ+/MST3N
), P < 0.01; and Lu243Z versus Lu(lacZ+/Lu-MST3N+), P < 0.001. These analyses were performed by either including or excluding
the survivor from the group of Lu(lacZ+/MST3N
)-challenged rabbits in
the analysis; however, this did not affect the significance levels.
| |
DISCUSSION |
|---|
|
|
|---|
The identification and characterization of the
Leporipoxvirus
2,3-sialyltransferase represent the first
description of a natural virus-encoded glycosyltransferase involved in
the biosynthesis of glycoproteins. The lack of strong amino acid
similarity makes it difficult to assign the MYXV enzyme to any of the
known
2,3-sialyltransferase classes ST3Gal-I to -IV (56),
suggesting that the enzyme may have unique acceptor specificity. The
closest similarities to the MYXV
2,3-sialyltransferase are the
sialyltransferase classes ST3Gal-III (human [31], 36%
identity and 54% similarity) and ST3Gal-IV (human
[32], 43% identity and 60% similarity). Both ST3Gal-III and ST3Gal-IV enzymes utilize N-glycan terminated
with Gal
1,3GlcNAc (type I; Lewisc [Lec])
and Gal
1,4GlcNAc (type II; N-acetyllactosamine
[LacNAc]) disaccharides. However, ST3Gal-III enzymes
preferentially utilize type I acceptors, while the ST3Gal-IV
enzymes show the highest level of activity toward terminal type
II disaccharides. Human ST3Gal-IV also utilizes Gal
1,3GalNAc (type
III; Thomsen-Friedenreich [TF] disaccharide) acceptors of O-linked
glycoprotein and glycolipids, whereas the ST3Gal-III enzymes show
negligible activity toward these glycoconjugates (32). The
asialofetuin glycoprotein contains three N-glycan chains
terminated with type II disaccharide (43), which are acceptor substrates for the MYXV
2,3-sialyltransferase. Under the in
vitro conditions described here, the MYXV
2,3-sialyltransferase does
not contain appreciable substrate specificity toward the terminal
O-linked type II or type III disaccharides of asialofetuin (17, 43). Therefore, the MST3N-encoded sialyltransferase is most similar in activity to the human ST3Gal-III, N-glycan
Gal
1,3(4)GlcNAc
2,3-sialyltransferase (32).
Inactivation of the MST3N gene in the Lu grade I virulent virus
resulted in generation of the mildly attenuated virus with grade II
virulence, establishing that the sialyltransferase is not required for
infection or induction of clinical myxomatosis in genetically
susceptible laboratory rabbits. In the absence of sialyltransferase
expression, disease symptoms are delayed, suggesting the MYXV
2,3-sialyltransferase may act synergistically with other virulence
factors. The MYXV
2,3-sialyltransferase may be required when
infecting certain cell types, for example, lymphocytes (44)
complementing a cellular deficiency in ST3Gal activity (33),
for correct sialylation of virus-expressed glycoproteins for optimal
structure, stability, and biological function.
Terminal Sia of glycoconjugates are known to play important functions
in cell-cell recognition (61). We speculate that
MYXV-induced
2,3-sialylation of viral or host glycoproteins could
also have some influence in regulating the host's innate responses to
virus infection. Many bacteria (e.g., Neisseria) and
parasites (e.g., Trypanosoma) express sialyltransferase
activities and salvage host Sia, attaching it to their own surface and
inhibiting complement-mediated cell lysis and masking of antigenic
sites (60). It has been proposed that macrophages contain a
lectin-like activity that recognizes surface asialoglycoconjugates of
apoptotic cells that are masked with Sia on normal cells
(50). Increased expression of cell surface
sialoglycoconjugates and the associated increase in negative charge
have also been correlated with resistance to killing of target cells by
activated NK cells (7). Enhanced expression of surface
sialoglycoconjugates could mask MYXV-infected cells from components of
the host's innate responses, allowing increased viral replication and
tissue dissemination prior to the development of a specific immune response.
Altered sialylation of glycoproteins expressed by MYXV-infected cells
could also affect cell surface ligand-receptor interactions. The
sialoadhesin family of I-type lectins are immunoglobulin
superfamily proteins which act as Sia-dependent adhesion molecules. The
sialoadhesin family includes sialoadhesin, expressed on macrophages
in lymphoid tissues and at sites of inflammation, and CD33,
expressed on myeloid cells and macrophages (10, 11). Both
sialoadhesin and CD33 bind terminal trisaccharides
Sia
2,3Gal
1,3GlcNAc and Sia
2,3Gal
1,4GlcNAc, which are the
proposed products of the MYXV
2,3-sialyltransferase. In association
with a GlcNAc
1,3/4-fucosyltransferase, the MYXV
2,3-sialyltransferase could also form the structures sialyl-Lewis a
(sLea; Sia
2,3Gal
1,3[Fuc
1,4]GlcNAc) and
sialyl-Lewis x (sLex;
Sia
2,3Gal
1,4[Fuc
1,3]GlcNAc), which are counterreceptors for the C-type lectin family of Sia binding adhesion proteins, E-, P-, and
L-selectins involved in regulation of cell trafficking in inflammation
and immune responses (3, 61). The presence of
2,3-sialylated N-glycan on MYXV-expressed soluble
glycoproteins could result in the binding and blockage of these
Sia-dependent receptors, resulting in the inhibition of (i)
inflammatory cell migration to the sites of virus replication, (ii)
homing of lymphocytes to lymphoid tissues, and (iii) adhesion and
stimulation of immune cells. Alternatively, expression of
Sia
2,3-linked glycoproteins on viral particles or infected cells
could mediate specific binding and infection of cells expressing
Sia-dependent receptors assisting in the dissemination of the virus
through the host's tissues. Enhanced tumor cell surface sialylation of
glycoconjugates has been correlated with increased metastatic
capability mediated by Sia-dependent receptor binding (30).
In poxvirus-infected cells, the TGN membranes contribute to the
outermost membrane of the secreted extracellular enveloped virus (EEV)
(51). It has been demonstrated that treatment of tissue
culture cells with sialidase enhanced purified VACV EEV binding and
infectivity by 50%, whereas intracellular mature virus (IMV) binding
was only marginally increased (59). It has also been shown
that antiserum directed against the glycolipid asialo-GM1 inhibited
VACV infection of mouse ovaries (28). Together these observations suggest that the VACV particles contain receptors for
asialoglycoconjugates, possibly cellularly derived sialyltransferases that are usually resident in the TGN. Expression of the virus encoded
2,3-sialyltransferase on the outer membrane of the
Leporipoxvirus EEV or on the surface of infected cells could
result in enhanced binding to terminal type I or type II disaccharides
of glycoproteins expressed on the surface of target cells.
The MYXV sialyltransferase is unlikely to be the only example of a virally encoded glycosyltransferase, because unusual virus-directed glycosylation has been observed with the Paramecium chlorella virus (63). Although a chlorella virus hyaluronan synthase gene has been characterized (16), genes encoding putative glycosyltransferases involved in the biosynthesis of the oligosaccharide of glycoproteins or glycolipids have not been identified. The list of known glycosyltransferase genes appearing in the databases is growing; however, there remain to be identified a large number of genes corresponding to the estimated >150 different glycosyltransferase activities. The complete nucleotide sequences of a number of viruses with large DNA genomes have been determined in recent years, and many ORFs have been identified which encode proteins of unknown function. Some of these uncharacterized viral proteins are potential type II integral membrane proteins characteristic of glycosyltransferases. With the future identification of new examples of glycosyltransferase genes, it is likely that some of these viral ORFs will also be shown to encode enzymes involved in the biosynthesis of oligosaccharide attached to glycoproteins or glycolipids.
| |
ACKNOWLEDGMENTS |
|---|
We thank Bob Seamark and Tony Robinson for critically reading the manuscript, Kelly White for technical assistance, and Robert Forrester for statistical advice.
This research was supported by the Australian Government's Cooperative Research Centres Program.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: CSIRO Wildlife and Ecology, GPO Box 284, Canberra, ACT 2601, Australia. Phone: 61 (02) 6242 1717. Fax: 61 (02) 6242 1511. E-mail: R.Jackson{at}dwe.csiro.au.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Albagli, O., P. Dhordain, C. Deweindt, G. Lecocq, and D. Leprince. 1995. The BTB/POZ domain: a new protein-protein interaction motif common to DNA- and actin-binding proteins. Cell Growth Differ. 6:1193-1198[Abstract]. |
| 2. |
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402 |
| 3. | Bevilacqua, M. P., and R. M. Nelson. 1993. Selectins. J. Clin. Investig. 91:379-387. |
| 4. | Bork, P., and R. F. Doolittle. 1994. Drosophila kelch motif is derived from a common enzyme fold. J. Mol. Biol. 236:1277-1282[Medline]. |
| 5. | Bouvier, M. 1954. Quelques remarques sur la myxomatose. Epizootie de 1949 au Brésil (Région de Campinas, Est Sao-Paulo). Bull. Off. Int. Epizoot. 46:76-77. |
| 6. |
Brown, C. K.,
P. C. Turner, and R. W. Moyer.
1991.
Molecular characterization of the vaccinia virus hemagglutinin gene.
J. Virol.
65:3598-3606 |
| 7. | Brutkiewicz, R. R., and R. M. Welsh. 1995. Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. J. Virol. 69:3967-3971[Medline]. |
| 8. | Cavallaro, K. F., and J. J. Esposito. 1992. Sequences of the raccoon poxvirus hemagglutinin protein. Virology 190:434-439[Medline]. |
| 9. |
Chang-Yeh, A.,
D. E. Mold, and R. C. Huang.
1991.
Identification of a novel murine IAP-promoted placenta-expressed gene.
Nucleic Acids Res.
19:3667-3672 |
| 10. | Crocker, P. R., A. Hartnell, J. Munday, and D. Nath. 1997. The potential role of sialoadhesin as a macrophage recognition molecule in heath and disease. Glycoconj. J. 14:601-609[Medline]. |
| 11. | Crocker, P. R., S. Kelm, A. Hartnell, S. Freeman, D. Nath, M. Vinson, and S. Mucklow. 1996. Sialoadhesion and related cellular recognition molecules of the immunoglobulin superfamily. Biochem. Soc. Trans. 24:150-156[Medline]. |
| 12. |
Datta, A. K., and J. C. Paulson.
1995.
The sialyltransferase "sialylmotif" participates in binding the donor substrate CMP-NeuAc.
J. Biol. Chem.
270:1497-1500 |
| 13. |
Datta, A. K.,
A. Sinha, and J. C. Paulson.
1998.
Mutation of the sialyltransferase S-sialylmotif alters the kinetics of the donor and acceptor substrates.
J. Biol. Chem.
273:9608-9614 |
| 14. | Davison, A. J., and B. Moss. 1989. Structure of vaccinia virus early promoters. J. Mol. Biol. 210:749-769[Medline]. |
| 15. | Davison, A. J., and B. Moss. 1989. Structure of vaccinia virus late promoters. J. Mol. Biol. 210:771-784[Medline]. |
| 16. |
DeAngelis, P. L.,
W. Jing,
M. V. Graves,
D. E. Burbank, and J. L. Van Etten.
1997.
Hyaluronan synthase of chlorella virus PBCV-1.
Science
278:1800-1803 |
| 17. |
Edge, A. S., and R. G. Spiro.
1987.
Presence of an O-glycosidically linked hexasaccharide in fetuin.
J. Biol. Chem.
262:16135-16141 |
| 18. | Esposito, J. J., D. Baxby, D. N. Black, S. Dales, G. Darai, K. R. Dumbell, R. R. Granados, W. K. Joklik, G. McFadden, B. Moss, R. W. Moyer, D. J. Pickup, A. J. Robinson, and D. N. Tripathy. 1995. Poxviridae, p. 79-91. In F. A. Murphy, C. M. Fauquet, D. H. L. Bishop, S. A. Ghabrial, A. W. Jarvis, G. P. Martelli, M. A. Mayo, and M. D. Summers (ed.), Virus taxonomy: the classification and nomenclature of viruses. The Sixth Report of the International Committee on Taxonomy of Viruses. Springer-Verlag, Vienna, Austria. |
| 19. |
Falkner, F. G., and B. Moss.
1990.
Transient dominant selection of recombinant vaccinia viruses.
J. Virol.
64:3108-3111 |
| 20. | Fenner, F. 1994. Myxoma virus, p. 59-70. In A. D. M. E. Osterhaus (ed.), Virus infections of vertebrates, vol. 5. Virus infections of rodents and lagomorphs. Elsevier Science B.V., Amsterdam, The Netherlands. |
| 21. | Fenner, F., and I. D. Marshall. 1957. A comparison of the virulence for European rabbits (Oryctolagus cuniculus) of strains of myxoma virus recovered in the field in Australia, Europe and America. J. Hyg. 55:149-191. |
| 22. |
Garcés, J.,
K. Masternak,
B. Kunz, and R. Wittek.
1993.
Reactivation of transcription from a vaccinia virus early promoter late in infection.
J. Virol.
67:5394-5401 |
| 23. | Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-266[Medline]. |
| 24. | Hansen, J. E., O. Lund, N. Tolstrup, A. A. Gooley, K. L. Williams, and S. Brunak. 1998. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj. J. 15:115-130[Medline]. |
| 25. |
Jackson, R. J., and H. G. Bults.
1992.
The myxoma virus thymidine kinase gene: sequence and transcriptional mapping.
J. Gen. Virol.
73:323-328 |
| 26. | Jackson, R. J., and D. F. Hall. 1998. The myxoma virus EcoRI-O fragment encodes the DNA binding core protein and the major envelope protein of extracellular poxvirus. Virus Genes 17:55-62[Medline]. |
| 27. |
Jackson, R. J.,
D. F. Hall, and P. J. Kerr.
1996.
Construction of recombinant myxoma viruses expressing foreign genes from different intergenic sites without associated attenuation.
J. Gen. Virol.
77:1569-1575 |
| 28. | Karupiah, G., and R. V. Blanden. 1990. Anti-asialo-GM1 inhibits vaccinia virus infection of murine ovaries: asialo-GM1 as an additional virus receptor? Immunol. Cell. Biol. 68:343-346. |
| 29. | Kerr, P. J., and R. J. Jackson. 1995. Myxoma virus as a vaccine vector for rabbits: antibody levels to influenza virus haemagglutinin presented by a recombinant myxoma virus. Vaccine 13:1722-1726[Medline]. |
| 30. | Kim, Y. J., and A. Varki. 1997. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj. J. 14:569-576[Medline]. |
| 31. |
Kitagawa, H., and J. C. Paulson.
1993.
Cloning and expression of human Gal 1,3(4)GlcNAc alpha 2,3-sialyltransferase.
Biochem. Biophys. Res. Commun.
194:375-382[Medline].
|
| 32. |
Kitagawa, H., and J. C. Paulson.
1994.
Cloning of a novel 2,3-sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups.
J. Biol. Chem.
269:1394-1401 |
| 33. |
Kitagawa, H., and J. C. Paulson.
1994.
Differential expression of five sialyltransferase genes in human tissues.
J. Biol. Chem.
269:17872-17878 |
| 34. | Lundberg, K. S., D. D. Shoemaker, M. W. Adams, J. M. Short, J. A. Sorge, and E. J. Mathur. 1991. High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus. Gene 108:1-6[Medline]. |
| 35. | Massung, R. F., J. J. Esposito, L.-I. Liu, J. Qi, T. R. Utterback, J. C. Knight, L. Aubin, T. E. Yuran, J. M. Parsons, V. N. Loparev, N. A. Selivanov, K. F. Cavallaro, A. R. Kerlavage, B. W. J. Mahy, and J. C. Venter. 1993. Potential virulence determinants in terminal regions of variola smallpox virus genome. Nature 366:748-751[Medline]. |
| 36. | McFadden, G., and M. Barry. 1998. How poxviruses oppose apoptosis. Semin. Virol. 8:429-442. |
| 37. | McFadden, G., and K. Graham. 1994. Modulation of cytokine networks by poxviruses: the myxoma virus model. Semin. Virol. 5:421-429. |
| 38. | McFadden, G., A. Lalani, H. Everett, P. Nash, and X. Xu. 1998. Virus-encoded receptors for cytokines and chemokines. Semin. Cell. Dev. Biol. 9:359-368[Medline]. |
| 39. | McMahan, C. J., J. L. Slack, B. Mosley, D. Cosman, S. D. Lupton, L. L. Brunton, C. E. Grubin, J. M. Wignall, N. A. Jenkins, C. I. Brannan, N. G. Copeland, K. Huebner, C. M. Croce, L. A. Cannizzarro, D. Benjamin, S. K. Dower, M. K. Spriggs, and J. E. Sims. 1991. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 10:2821-2832[Medline]. |
| 40. | Moses, A. 1911. O virus do mixoma dos coelhos. Mem. Inst. Oswaldo Cruz 3:46-53. |
| 41. | Mykytowycz, R. 1953. An attenuated strain of the myxomatosis virus recovered from the field. Nature 172:448-449[Medline]. |
| 42. | Nakai, K., and M. Kanehisa. 1992. A knowledge base for predicting protein localization sites in eukaryotic cells. Genomics 14:897-911[Medline]. |
| 43. |
Nilsson, B.,
N. E. Nordén, and S. Svensson.
1979.
Structural studies on the carbohydrate portion of fetuin.
J. Biol. Chem.
254:4545-4553 |
| 44. |
Opgenorth, A.,
K. Graham,
N. Nation,
D. Strayer, and G. McFadden.
1992.
Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor.
J. Virol.
66:4720-4731 |
| 45. | Parks, R. J., B. D. Lichty, C. Karakis, and D. H. Evans. 1994. Characterization of the Shope fibroma virus DNA ligase gene. Virology 202:642-650[Medline]. |
| 46. | Payne, L. G. 1992. Characterization of vaccinia virus glycoprotein by monoclonal antibody precipitation. Virology 187:251-260[Medline]. |
| 47. |
Robinson, D. N., and L. Cooley.
1997.
Drosophila kelch is an oligomeric ring canal actin organizer.
J. Cell Biol.
138:799-810 |
| 48. |
Roy, A.,
C. F. Lu,
D. L. Marykwas,
P. N. Lipke, and J. Kurjan.
1991.
The AGA1 product is involved in cell surface attachment of the Saccharomyces cerevisiae cell adhesion glycoprotein a-agglutinin.
Mol. Cell. Biol.
11:4196-4206 |
| 49. | Sasaki, K. 1996. Molecular cloning and characterization of sialyltransferases. Trends Glycosci. Glycotechnol. 8:195-215. |
| 50. | Savill, J., V. Fadok, P. Henson, and C. Haslett. 1993. Phagocyte recognition of cells undergoing apoptosis. Immunol. Today 14:131-136[Medline]. |
| 51. |
Schmelz, M.,
B. Sodeik,
M. Ericsson,
E. J. Wolffe,
H. Shida,
G. Hiller, and G. Griffiths.
1994.
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network.
J. Virol.
68:130-147 |
| 52. |
Schmid, M. F.,
J. M. Agris,
J. Jakana,
P. Matsudaira, and W. Chiu.
1994.
Three-dimensional structure of a single filament in the Limulus acrosomal bundle: scruin binds to homologous helix-loop-beta motifs in actin.
J. Cell Biol.
124:341-350 |
| 53. | Shope, R. E. 1932. A filterable virus causing a tumor-like condition in rabbits and its relationship to virus myxomatosum. J. Exp. Med. 56:803-822[Abstract]. |
| 54. | Sonnhammer, E. L., S. R. Eddy, and R. Durbin. 1997. Pfam: a comprehensive database of protein domain families based on seed alignments. Proteins 28:405-420[Medline]. |
| 55. | Tonissen, K. F., and P. A. Krieg. 1993. Two neural-cell adhesion molecule (NCAM)-encoding genes in Xenopus laevis are expressed during development and in adult tissues. Gene 127:243-247[Medline]. |
| 56. | Tsuji, S., A. K. Datta, and J. C. Paulson. 1996. Systematic nomenclature for sialyltransferases. Glycobiology 6:R5-R7. |
| 57. | Upton, C., J. L. Macen, D. S. Wishart, and G. McFadden. 1990. Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology 179:618-631[Medline]. |
| 58. |
Upton, C.,
L. Schiff,
S. A. Rice,
T. Dowdeswell,
X. Yang, and G. McFadden.
1994.
A poxvirus protein with a RING finger motif binds zinc and localizes in virus factories.
J. Virol.
68:4186-4195 |
| 59. | Vanderplasschen, A., and G. L. Smith. 1997. A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors. J. Virol. 71:4032-4041[Abstract]. |
| 60. |
Varki, A.
1993.
Biological roles of oligosaccharides: all the theories are correct.
Glycobiology
3:97-130 |
| 61. | Varki, A. 1997. Sialic acids as ligands in recognition phenomena. FASEB J. 11:248-255[Abstract]. |
| 62. | von Bulow, M., H. Heid, H. Hess, and W. W. Franke. 1995. Molecular nature of calicin, a major basic protein of the mammalian sperm head cytoskeleton. Exp. Cell. Res. 219:407-413[Medline]. |
| 63. |
Wang, I.-N.,
Y. Li,
Q. Que,
M. Bhattacharya,
L. C. Lane,
W. G. Chaney, and J. L. Van Etten.
1993.
Evidence for virus-encoded glycosylation specificity.
Proc. Natl. Acad. Sci. USA
90:3840-3844 |
| 64. | Way, M., M. Sanders, M. Chafel, Y. H. Tu, A. Knight, and P. Matsudaira. 1995. Beta-scruin, a homologue of the actin crosslinking protein scruin, is localized to the acrosomal vesicle of Limulus sperm. J. Cell Sci. 108:3155-3162[Abstract]. |
| 65. |
Way, M.,
M. Sanders,
C. Garcia,
J. Sakai, and P. Matsudaira.
1995.
Sequence and domain organization of scruin, an actin-cross-linking protein in the acrosomal process of Limulus sperm.
J. Cell Biol.
128:51-60 |
| 66. | Xue, F., and L. Cooley. 1993. Kelch encodes a component of intercellular bridges in Drosophila egg chambers. Cell 72:681-693[Medline]. |
| 67. |
Yuen, L., and B. Moss.
1987.
Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes.
Proc. Natl. Acad. Sci. USA
84:6417-6421 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»